Wolverine Trading, LLC Apellis Pharmaceuticals, Inc. Put Options Transaction History

Wolverine Trading, LLC

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$28.84 - $41.15 $273,980 - $390,925	9,500 Added 43.58%	31,300 $902,000
Q2 2024 Aug 14, 2024	SELL	$38.07 - $59.71 $137,052 - $214,956	-3,600 Reduced 14.17%	21,800 $836,000
Q1 2024 May 15, 2024	SELL	$55.39 - $72.47 $293,567 - $384,091	-5,300 Reduced 17.26%	25,400 $1.49 Million
Q4 2023 Feb 14, 2024	SELL	$37.14 - $64.82 $386,256 - $674,127	-10,400 Reduced 25.3%	30,700 $1.84 Million
Q3 2023 Nov 15, 2023	BUY	$23.65 - $89.22 $115,885 - $437,178	4,900 Added 13.54%	41,100 $1.56 Million
Q2 2023 Aug 23, 2023	BUY	$76.68 - $93.31 $1.43 Million - $1.74 Million	18,600 Added 105.68%	36,200 $3.3 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $819,984 - $1.18 Million	17,600 New	17,600 $1.16 Million
Q2 2022 Aug 15, 2022	SELL	$35.07 - $59.21 $1.24 Million - $2.1 Million	-35,400 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$35.46 - $54.12 $1.17 Million - $1.79 Million	-33,000 Reduced 48.25%	35,400 $1.75 Million
Q3 2021 Nov 12, 2021	BUY	$31.4 - $69.84 $2.15 Million - $4.78 Million	68,400 New	68,400 $2.32 Million

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.